Novartis post-Sandoz spinoff is a pure-play innovative pharma with strong cardiovascular (Entresto, Leqvio) and oncology (Pluvicto, Kisqali) franchises. Pluvicto radioligand expansion into earlier prostate cancer lines is a multi-billion opportunity. Leqvio twice-yearly LDL injection finally hitting volume after slow launch. M&A firepower available with deleveraged balance sheet.
Thesis reviewed May 29, 2026
Novartis AG is headquartered in Switzerland, which is currently showing moderate signals.
🇨🇭Switzerland48NEUTRALView Switzerland risk detail →💊Pharma0NEUTRAL| Ticker | Company | Score | Gap | Signal Δ | Action |
|---|---|---|---|---|---|
| LLY | Eli Lilly and Company | 50 | +24% | ↓0% | EARLY |
| AZN | AstraZeneca PLC | 50 | +11% | ↓0% | EARLY |
| SNY | Sanofi | 50 | +14% | ↓0% | EARLY |
| GSK | GSK plc | 50 | +8% | ↓0% | NEUTRAL |
| PFE | Pfizer Inc. | 50 | +6% | ↓0% | NEUTRAL |
| NVO | Novo Nordisk A/S | 50 | +15% | ↓0% | EARLY |
| RDY | Dr Reddy's Laboratories Ltd | 50 | +7% | ↓0% | NEUTRAL |
Investors who hold NVS may also have indirect exposure through these country funds.
Pluvicto PSMAfore Phase 3 supports earlier-line label expansion
Leqvio Q1 scripts up 60% as Medicare reimbursement clears
Novartis announces $5B bolt-on acquisition in radiopharma
Estimates · Yahoo Finance · Not audited figures